Autosomal recessive spastic paraplegia type 32

Autosomal recessive spastic paraplegia type 32 (SPG32) is an extremely rare hereditary spastic paraplegia caused by mutations in the KIF1A gene (though initially mapped and sometimes associated with chromosome 14q12-q21). It is characterized by progressive spasticity and weakness of the lower limbs due to degeneration of the longest motor neurons in the corticospinal tract. The condition primarily affects the nervous system, particularly the upper motor neurons that control voluntary movement in the legs. Patients with SPG32 typically present in childhood with progressive difficulty walking, increased muscle tone (spasticity) in the lower extremities, and exaggerated deep tendon reflexes. Additional neurological features may include intellectual disability, thin corpus callosum, and cortical and cerebellar atrophy on brain imaging, suggesting this is a complicated form of hereditary spastic paraplegia rather than a pure form. Some patients may also exhibit peripheral neuropathy. There is currently no cure or disease-modifying treatment for SPG32. Management is supportive and symptomatic, focusing on physical therapy to maintain mobility and reduce contractures, antispasticity medications such as baclofen or tizanidine, and orthopedic interventions as needed. Occupational therapy and assistive devices may help maintain functional independence. Given the extreme rarity of this condition, clinical data are limited and largely derived from individual case reports or small family studies.

Common questions about Autosomal recessive spastic paraplegia type 32